Quinolines and derivatives
![Medchemexpress LLC 4h-1-Benzopyran-4-one, 6-[3-(4-morpholinyl)propyl]-2-thieno[3,2-c]pyridin-6-yl-, oxime, hydrochloride | 2133294-96-7 | 98.6% | 457.97 | 25 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/default.jpg-250.jpg)
Medchemexpress LLC 4h-1-Benzopyran-4-one, 6-[3-(4-morpholinyl)propyl]-2-thieno[3,2-c]pyridin-6-yl-, oxime, hydrochloride | 2133294-96-7 | 98.6% | 457.97 | 25 MG
Foliglurax monohydrochloride is a highly selective and potent, brain-penetrant metabotropic glutamate receptor 4 positive allosteric modulator (mGluR4 PAM) with an EC50 of 79 nM. It exhibits an antiparkinsonian effect and is for research use only.
- Highly selective and potent mGluR4 PAM.
- Brain-penetrant.
- Exhibits an antiparkinsonian effect.
- For research use only.
- Potentially revolutionizing mGlu4 receptor drug targeting in CNS disorders.
Medchemexpress LLC Liproxstatin-1 | 950455-15-9 | 99.70% | 200 MG
Liproxstatin-1 is identified as a potent ferroptosis inhibitor, effectively suppressing ferroptotic cell death with an IC50 value of 22 nM. It demonstrates anti-ferroptotic activity across various cell types, including fibroblasts, lymphocytes, and mouse embryonic fibroblasts (MEFs). Studies have also indicated its ability to suppress ferroptosis in vivo, specifically in human cells, Gpx4 deficient kidney cells, and in an ischemia/reperfusion-induced tissue injury model.
- Potent ferroptosis inhibitor.
- Inhibits ferroptotic cell death with an IC50 of 22 nM.
- Shows anti-ferroptotic activity in mouse embryonic fibroblasts with an IC50 of approximately 38 nM.
- Suppresses ferroptosis in human cells.
- Suppresses ferroptosis in Gpx4 deficient kidney.
- Suppresses ferroptosis in an ischemia/reperfusion-induced tissue injury model.
Apexbio Technology LLC Coenzyme Q10 303-98-0 200mg
Coenzyme Q10 (CAS 303-98-0) is a lipophilic benzoquinone involved in mitochondrial electron transport and cellular energy production It functions as an essential electron carrier within the electron transport chain facilitating ATP synthesis and exhibiting antioxidant properties by mitigating oxidative damage Coenzyme Q10 is frequently studied for its role in cellular metabolism bioenergetics and redox homeostasis Due to its involvement in mitochondrial function it is widely applied in research on metabolic disorders neurodegeneration and cardiovascular diseases The compound is soluble in organic solvents such as chloroform benzene and carbon tetrachloride For optimal stability it should be stored sealed in cool and dry conditions
Apexbio Technology LLC Nicotinamide Riboside Chloride (NIAGEN)(Synonyms: NR Chloride, Niagen, Nicotinamide Riboside Chloride, NR-Cl, Nicotinamide Riboside Cl), 200mg, CAS: 23111-00-4.
Nicotinamide Riboside Chloride (NIAGEN CAS 23111-00-4) is a small molecule precursor of nicotinamide adenine dinucleotide (NAD ) an essential cofactor implicated in energy metabolism and cellular homeostasis Upon oral administration it effectively elevates intracellular NAD levels subsequently modulating the activity of NAD -dependent sirtuin enzymes particularly SIRT1 and SIRT3 Experimental evidence indicates that Nicotinamide Riboside Chloride enhances oxidative metabolism and mitigates metabolic dysfunction induced by high-fat dietary conditions Additionally studies employing Alzheimer s disease transgenic mouse models suggest that this compound can reduce cognitive decline supporting its use in biomedical research targeting metabolic and neurodegenerative conditions
Medchemexpress LLC Indisulam | 165668-41-7 | MFCD00945325 | 99.8% | 385.85 | 200 MG
Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. This sulfonamide agent targets the G1 phase of the cell cycle, causing a blockade in the G1/S transition. It achieves this by inhibiting the activation of both CDK2 and cyclin E. Additionally, it targets splicing by inducing RBM39 degradation via recruitment to DCAF15.
- Carbonic anhydrase inhibitor
- Exhibits anticancer activity
- Sulfonamide agent
- Targets G1 phase of the cell cycle
- Inhibits CDK2 and cyclin E activation
- Induces RBM39 degradation
- Involved in splicing modulation
Medchemexpress LLC Nilutamide | 63612-50-0 | 99.7% | 317.22 | 200 MG
Nilutamide is an orally active nonsteroidal androgen receptor antagonist. It has affinity for androgen receptors but not for progestogen, estrogen, or glucocorticoid receptors. It can be used for research on prostate cancer and also exhibits antischistosomal properties. It inhibits hexobarbital hydroxylase, benzphetamine N-demethylase, benzo(a)pyrene hydroxylase, and 7-ethoxycoumarin O-deethylase activities in human liver microsomes.
- Orally active nonsteroidal androgen receptor antagonist
- Used for research on prostate cancer
- Exhibits antischistosomal properties
- Inhibits hexobarbital hydroxylase and other enzyme activities
Apexbio Technology LLC AM966 1228690-19-4 200mg
AM966 (CAS 1228690-19-4) is an orally bioavailable small-molecule antagonist that selectively targets Lysophosphatidic acid type 1 receptor (LPA1) AM966 exhibits potent inhibitory activity against LPA1 receptors from humans and mice with IC50 values of approximately 17 nM and 19 nM respectively demonstrating selectivity over other LPA receptor subtypes (LPA2 5) In vitro AM966 blocks LPA-mediated chemotactic responses in IMR-90 human lung fibroblasts A2058 human melanoma cells and CHO cell lines In vivo AM966 effectively attenuates lung fibrosis inflammation and associated weight loss in bleomycin-induced murine pulmonary fibrosis models highlighting its utility in research on fibrotic diseases
Medchemexpress LLC Finasteride | 98319-26-7 | MFCD00869737 | 100.0% | 372.54 | 200 MG
Finasteride is an orally active and competitive 5α-reductase inhibitor primarily targeting type II 5α-reductase. It works by blocking the conversion of testosterone into dihydrotestosterone (DHT), thereby reducing DHT levels in prostate cells and scalp hair follicles. This compound is used in research for conditions such as benign prostatic hyperplasia (BPH) and androgenic alopecia.
- Orally active and competitive 5α-reductase inhibitor
- Exhibits high affinity for type II 5α-reductase enzyme
- Reduces prostatic size and increases urine flow rate
- Promotes hair growth and prevents hair loss
- Suitable for research on benign prostatic hyperplasia (BPH)
- Suitable for research on androgenic alopecia
- Suppresses DHT levels in plasma and prostate
Medchemexpress LLC Amisulpride | 71675-85-9 | MFCD00866691 | 99.8% | C17H27N3O4S | 200 MG
Amisulpride is a racemic (50:50) mixture of R-Amisulpride and S-Amisulpride. It acts as a dopamine D2/D3 receptor antagonist with Ki values of 2.8 nM for human dopamine D2 and 3.2 nM for human dopamine D3 receptors. Amisulpride also functions as a 5-HT7 receptor antagonist with a Ki of 44 nM, making it suitable for use in psychiatric research.
- Racemic mixture
- Dopamine D2/D3 receptor antagonist
- 5-HT7 receptor antagonist
- Suitable for psychiatric research
- D3 receptor Ki: 3.2 nM
- Human D2 receptor Ki: 2.8 nM
- 5-HT7 receptor Ki: 44 nM
- Inhibits quinpirole-elicited [3H]thymidine incorporation
- Increases dopamine release from rat striatum slices
- Increases dopamine synthesis in rat striatum and limbic system
- Increases extracellular dopamine levels
- Decreases striatal ACh levels
- Increases duration of swimming behavior
Apexbio Technology LLC MI-2(Synonyms: Menin-MLL Inhibitor MI-2, MI2, MI 2, Menin inhibitor MI-2), 200mg, CAS: 1271738-62-5.
MI-2 (CAS 1271738-62-5) is a small molecule inhibitor targeting the menin-MLL protein-protein interaction with an IC50 of 0 45 M The formation of menin-MLL fusion protein complexes resulting from chromosomal rearrangements plays an essential role in the pathogenesis of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) MI-2 selectively binds wild-type menin disrupting its interaction with MLL-fusion proteins such as MLL-AF9 thereby inhibiting cellular proliferation and colony formation in MLL-AF9-transduced mouse bone marrow cells MI-2 serves as a research tool in studies of leukemia biology and menin-associated oncogenesis
TARGETMOL CHEMICALS INC Aprepitant 200MG
Also available in 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg and bulk. Please contact Fisher for quotes. Aprepitant is a Substance P/Neurokinin-1 Receptor Antagonist. The mechanism of action of aprepitant is as a Neurokinin 1 Antagonist, and Cytochrome P450 3A4 Inhibitor, and Cytochrome P450 2C9 Inducer, and Cytochrome P450 3A4 Inducer. Purity 99.9%
Apexbio Technology LLC Iniparib (BSI-201) 160003-66-7 200mg
Iniparib (BSI-201) (CAS 160003-66-7) is a small-molecule inhibitor initially characterized as targeting poly(ADP-ribose) polymerase-1 (PARP1) It is designed to inhibit PARP1 by promoting oxidation of zinc finger motifs leading to zinc ejection and suppression of enzyme activity Iniparib exerts its biological activity primarily through metabolism into a C-nitroso intermediate which modifies cysteine residues in multiple proteins In cellular assays Iniparib demonstrates growth-inhibitory activity with reported IC50 values approximately ranging from 40 to 100 M in cancer cell lines Based on these pharmacological properties Iniparib holds research potential in oncology studies particularly in treatment-resistant and solid tumor models
Apexbio Technology LLC BGJ398(Synonyms: Infigratinib, NVP-BGJ398, BGJ-398, BGJ 398), 200mg, CAS: 872511-34-7.
BGJ398 (CAS 872511-34-7) also known as NVP-BGJ398 is an orally bioavailable small-molecule inhibitor targeting fibroblast growth factor receptors (FGFRs) It selectively inhibits receptor tyrosine kinase activity of FGFR1 FGFR2 FGFR3 and FGFR4 which are critical mediators in signal transduction pathways involved in cell proliferation differentiation and survival In preclinical studies BGJ398 suppresses proliferation and induces apoptosis in FGFR-dependent cancer cells additionally it demonstrates antitumor activity in xenograft tumor models BGJ398 is utilized as a research tool in oncology studies investigating FGFR-driven malignancies
Medchemexpress LLC NCT-503 | 1916571-90-8 | 99.7% | 408.48 g/mol | C20H23F3N4S | 200 MG
NCT-503 is a small-molecule inhibitor of phosphoglycerate dehydrogenase (PHGDH) with an IC50 of 2.5 μM, used as a research tool to probe serine biosynthesis pathways and PHGDH-dependent cancer biology in vitro and in vivo.
- Potent PHGDH inhibition with IC50 2.5 μM.
- High selectivity against other dehydrogenases and minimal GPCR cross-reactivity.
- Demonstrated activity in PHGDH-dependent cell lines and tumor xenograft models.
- Solid form with high purity suitable for biochemical and cellular assays.
- Recommended storage conditions for long-term stability.
Medchemexpress LLC Prostaglandin H2 | 42935-17-1 | MFCD00222079 | ≥95.0% | 352.47 | 50 UG
Prostaglandin H2 (PGH2) is an endothelium-derived contracting factor that can cause vasoconstriction. It serves as a common precursor for all prostaglandins and is generated by cells expressing cyclooxygenases. PGH2 can activate PGD2 receptors, induce eosinophil migration, inhibit platelet aggregation, and accelerate the formation of amyloid β1-42 oligomers. It is utilized in research concerning inflammation and neurological conditions, such as Alzheimer's disease.
- Induces eosinophil migration.
- Inhibits platelet aggregation.
- Accelerates formation of amyloid β1-42 oligomers.
- Used in inflammation research.
- Used in neurological disease research.